Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141627 | 0.85 | TDP1 (0.60) | TDP1TSHRSMN1; SMN2RECQLNPC1 | |
| SCHEMBL30072726 | 0.85 | TDP1 (0.60) | TDP1TSHRSMN1; SMN2RECQLNPC1 | |
| SCHEMBL2307746 | 0.82 | RAB9A (0.72) | TDP1SMN1; SMN2RECQLNPC1RAB9A | |
| SCHEMBL26132980 | 0.82 | RAB9A (0.57) | TDP1TSHRSMN1; SMN2RECQLNPC1 | |
| SCHEMBL10263950 | 0.81 | NPC1 (0.56) | TDP1TSHRSMN1; SMN2RECQLNPC1 | |
| SCHEMBL8489668 | 0.81 | NPC1 (0.56) | TDP1TSHRSMN1; SMN2RECQLNPC1 | |
| SCHEMBL9507212 | 0.81 | TDP1 (0.55) | TDP1TSHRSMN1; SMN2RECQLNPC1 | |
| SCHEMBL310065 | 0.81 | NPC1 (0.56) | TDP1TSHRSMN1; SMN2RECQLNPC1 | |
| SCHEMBL29229957 | 0.80 | TDP1 (0.69) | TDP1TSHRSMN1; SMN2RECQLNPC1 | |
| SCHEMBL1141905 | 0.80 | TDP1 (0.65) | TDP1TSHRSMN1; SMN2RECQLNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314111-B2 | Fused bicyclic motor inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | OSI Pharmaceuticals, LLC | 2011-09-08 | — | — | US | disclosed |
| US-20110190496-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-7923555-B2 | Fused bicyclic mTor inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | TDP1 4225/4885TSHR 4403/4885SMN1; SMN2 2973/4885 |
| US-20110190496-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | TDP1 4225/4885TSHR 4403/4885SMN1; SMN2 2973/4885 |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | MTOR, RICTOR, MAPKAP1 | TDP1 4225/4885TSHR 4403/4885SMN1; SMN2 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.